| 08.09.2025 07:00 | FAB | Belfast investor presentation | Reach |
| 04.09.2025 11:42 | ABDN, BRK, LEND | EARNINGS: Gem Diamonds revenue down; Brooks Macdonald outflows ease | Alliance |
| 04.09.2025 07:00 | FAB | Final Results | RNS |
| 28.08.2025 11:11 | SVNS, AVG, FDR | TRADING UPDATES: Avingtrans HS2 win; Metals Exploration's Runruno blow | Alliance |
| 28.08.2025 07:00 | FAB | Contract Win | RNS |
| 27.08.2025 14:24 | FAB | Fusion Antibodies hails new contracts worth USD460,000 | Alliance |
| 27.08.2025 07:00 | FAB | Contract wins with existing client | RNS |
| 26.08.2025 07:00 | FAB | Investor presentations | Reach |
| 05.08.2025 07:00 | FAB | Grant of U.S. Patent for OptiMAL | RNS |
| 24.07.2025 10:56 | FAB | Issue Notification: US Patent Update | RNS |
| 11.07.2025 07:00 | FAB | Director/PDMR Shareholding | RNS |
| 02.06.2025 07:00 | FAB | Total Voting Rights | RNS |
| 22.05.2025 22:51 | VEL, GLV, PHE | TRADING UPDATES: Poolbeg upsizes offer; Glenveagh backs outlook | Alliance |
| 22.05.2025 14:33 | FAB | Update on U.S. Patent for OptiMAL® | RNS |
| 08.05.2025 07:00 | FAB | Investor presentation | Reach |
| 07.05.2025 07:00 | FAB | Issue of shares to non-executive directors | RNS |
| 06.05.2025 10:53 | FAB | Director/PDMR Shareholding | RNS |
| 06.05.2025 10:38 | FAB | Holding(s) in Company | RNS |
| 06.05.2025 07:00 | FAB | Trading update | RNS |
| 30.04.2025 17:00 | FAB | Total Voting Rights | RNS |
| 24.04.2025 07:00 | FAB | Approval of grant funding | RNS |
| 11.04.2025 10:40 | FAB | Holding(s) in Company | RNS |
| 10.04.2025 12:47 | FAB | Holding(s) in Company | RNS |
| 07.04.2025 12:35 | FAB | Result of General Meeting | RNS |
| 31.03.2025 17:00 | FAB | Total Voting Rights | RNS |
| 24.03.2025 16:38 | FAB | Holding(s) in Company | RNS |
| 18.03.2025 07:00 | FAB | Placing to raise approximately £1.17 million | RNS |
| 27.02.2025 07:00 | FAB | Contract win | RNS |
| 31.01.2025 07:00 | FAB | OptiMAL R&D Update | RNS |
| 04.12.2024 12:18 | FAB | Fusion Antibodies receives approval of grant funding application | Alliance |
| 04.12.2024 11:31 | FAB | Approval of Grant Funding Application | RNS |
| 19.11.2024 13:10 | FAB | Fusion Antibodies interim loss narrows as revenue more than doubles | Alliance |
| 16.10.2024 13:23 | FAB | Director/PDMR Shareholding | RNS |
| 16.10.2024 07:00 | FAB | Issue of shares to non-executive directors | RNS |
| 08.10.2024 13:58 | FAB | IN BRIEF: Fusion Antibodies expects interim revenue to double | Alliance |
| 08.10.2024 12:32 | FAB | Result of AGM | RNS |
| 08.10.2024 07:00 | FAB | AGM statement and trading update | RNS |
| 02.10.2024 07:00 | FAB | Block admission six monthly return | RNS |
| 01.10.2024 15:33 | FAB | UK shareholder meetings calendar - next 7 days | Alliance |
| 12.09.2024 09:54 | FAB | Notice of AGM | RNS |
| 09.09.2024 12:35 | FAB | Director/PDMR Shareholding | RNS |
| 09.09.2024 07:00 | FAB | Investor presentation | Reach |
| 05.09.2024 12:15 | FAB | Director/PDMR Shareholding | RNS |
| 05.09.2024 07:00 | FAB | Final Results | RNS |
| 28.08.2024 13:52 | FAB | Fusion Antibodies expands agreement with National Cancer Institute | Alliance |
| 28.08.2024 11:12 | TYM, FAB | AIM WINNERS & LOSERS: Aquis expects GBP1 million hit on contract loss | Alliance |
| 28.08.2024 07:00 | FAB | Expansion to OptiMAL collaboration agreement | Reach |
